The global market is expected to enjoy a valuation of US$ 123.2 Billion by the end of the year 2023, and further expand at a CAGR of 5.2% to reach a valuation of ~US$ 205.3 Billion by the year 2033. According to the recent study by Future Market Insights, degenerative diseases are leading the market with an expected share of about 31.7% in the year 2023,within the global market.
Market Outlook:
Data Points
Market Insights
Market Value 2022
US$ 117.6 Billion
Market Value 2023
US$ 123.2 Billion
Market Value 2033
US$ 205.3 Billion
CAGR 2023-2033
5.2%
Market Share of Top 5 Countries (2022)
54.8%
Key Market Players List
Abbvie Inc, Alkermes Plc, Allergan Plc, AstraZeneca Plc, BIAL Group, Bristol-myers Squibb, Eisai Co, Ltd., Endo Pharmaceuticals, Eli Lilly and Co, and F. Hoffmann-La Roche Ltd.
The CNS or central nervous system is the coordinating or control mechanism of the animal body, including humans. Degeneration of nervous tissues or disorders in the brain and spinal cords is the prominent reason for several types of neurodegenerative diseases.
New research activities conducted in the sphere of mental health and psychiatric disorders have increased the demand for treatment and therapeutic opportunities available in the CNS treatment and therapy market.
The growth of CNS therapeutics for the soaring cases of mental illness and central nervous system disorders associated with faulty lifestyle is providing the necessary impetus for the establishment and growth of the CNS treatment and therapy market across the geographical regions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of CNS Treatment and Therapy Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033
The market value for CNS treatment and therapy was around 57.8% of the overall ~US$ 203.6 Billion of the global antibody therapy market in 2022.
The sale of CNS treatment and therapy expanded at a CAGR of 4.66% from 2017 to 2022.
Over the years, increased incidents of psychological disorders and nervous breakdown have emerged as a major concern across the globe. By the applications of several types of chemical formulations such as anaesthetic anti-Parkinson's drugs and antiepileptic drugs, the CNS treatment and therapy has relieved many patients across the globe, creating a huge market.
According to Parkinson's Foundation, the global count of patients suffering from Parkinson's disease is estimated to be 10 million in 2022. The diagnosis report for other nervous system disorder diseases have also increased significantly in the recent past and is estimated to reach 82 million by 2030. This situation creates ample of opportunity for pharmaceutical companies to generate revenues by delivering treatment and therapeutic options for the patients.
Increased government funding to accelerate the clinical development of newly discovered drugs is expected to fuel the rapid growth of the central nervous system therapeutics market during the forecast period. The introduction of new therapies like serotonin and norepinephrine reuptake inhibitors (SNRIs) have acquired huge traction within a short period of time.
Thus, owing to the aforementioned factors, the global CNS treatment and therapy market is projected to expand at a CAGR of 5.2% during the forecast period between 2023 and 2033.
H1-H2 Update
Market Statistics
Details
Jan-Jun (H1), 2021 (A)
3.99%
Jul-Dec (H2), 2021 (A)
5.13%
Jan-Jun (H1),2022 Projected (P)
3.70%
Jan-Jun (H1),2022 Outlook (O)
4.00%
Jul-Dec (H2), 2022 Outlook (O)
5.26%
Jul-Dec (H2), 2022 Projected (P)
5.03%
Jan-Jun (H1), 2023 Projected (P)
3.87%
BPS Change : H1,2022 (O) - H1,2022 (P)
30↑
BPS Change : H1,2022 (O) - H1,2021 (A)
1↑
BPS Change: H2, 2022 (O) - H2, 2022 (P)
22↑
BPS Change: H2, 2022 (O) - H2, 2021 (A)
12↑
What are the Key Opportunities for the Market Players?
According to the Alzheimer’s Association, the number of patients suffering from Alzheimer’s is predicted to reach nearly 13 billion in the USA alone by 2050. Alzheimer’s, along with other neurological disorders in the ageing population, is predicted to keep demand for CNS treatment and therapy services high in the US market and other regions as well.
New product launches by adopting upgraded techniques are the prospective growth strategy that is adopted by major market players operating in the central nervous system therapeutics market. For instance, the Corbus Pharmaceutical Inc. of Japan started the commercialization of the Lenabasum drug in Japan by entering into an agreement with Kaken pharmaceutical company in 2019.
The rising cases of mental health disorders among the general population has provided the necessary impetus for the central and regional governments to make necessary provisions for the treatment of CNS disorders. Canada released its first national strategy for controlling dementia by spending US$ 200 Million though the Canadian Institute of Health Research in 2019.
The global CNS therapeutics is categorized based on the class of drugs used for the treatment of central nervous system disorders. Immunomodulators and interferon are analysed to be constantly driving the central nervous treatment drug market by the innovation of therapeutic molecules implemented for the treatment of neurological diseases symptoms.
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining Demand for CNS Treatment and Therapy?
Strong guidelines for the approval of newly developed drug Formulations before introduction into the market hamper the competitive edge of pharmaceutical companies investing heavily in research and development. Failure rates of various newly introduced drugs for nervous system therapeutics is also higher, which poses a major challenge for the growth of the market.
The wide availability of generic drugs is also anticipated to limit the growth of private market players supplying neurological disorder drugs, anaesthetics, anti-Parkinson drugs and its other variants. Agreement with government organizations to supply neurological disease prevention products can be established to incur higher profit from the CNS treatment and therapy services.
The introduction of novel drug delivery systems in the past decade have faced the issue of its acceptance in healthcare sectors of all regions.
Dissemination of proper information to the CNS treatment and therapy centres is the underlying challenge that may hinder the market players from realizing their full potential.
Country-wise Insights
Country
USA
2023
31.70%
2033
31.20%
BPS Analysis
-52
Country
Germany
2023
6.70%
2033
7.20%
BPS Analysis
46
Country
UK
2023
5.70%
2033
5.70%
BPS Analysis
-3
Country
Canada
2023
5.70%
2033
5.70%
BPS Analysis
7
Country
China
2023
5.60%
2033
6.20%
BPS Analysis
59
What Makes the USA a Large Market for CNS Treatment and Therapy?
The USA is set to hold a total market share of about 31.7% in 2023.
The primary causes of these enormous market growth tendencies in the USA market includes rising percentage of the elderly population and the greatest level of healthcare spending. The demand within the global market is projected to rise as people become more aware of the neurodegenerative illnesses, autoimmune and inflammatory disorders, and their potential for treatment.
What is the Outlook of Germany in the CNS Treatment and Therapy Market?
Germany is set to hold a market share of nearly 6.7% in the global CNS treatment and therapy market in 2023.
Given the intricacy of the condition and the scarcity of accessible controlled research, among the most sensitive issues in neuro-oncology is the treatment of primary CNS lymphoma. The European Association of Neuro-Oncology established a multidisciplinary task force in 2013 to develop evidence-based recommendations for immunocompetent adults with primary CNS lymphoma.
The recommendations cover topics such as the management of aged patients as well as features of care for surgery, systemic and intrathecal chemotherapy, intense chemotherapy with autologous stem-cell transplantation, radiation, and ophthalmic symptoms. The recommendations should support doctors in their day-to-day work and decision-making, act as a foundation for next neuro-oncology studies, and increase market value in Germany.
How is the Market Expected to Grow in China?
China contributes about 5.6% revenue share to the global market.
China has become a significant market for anesthetics anti-Parkinson medications as a result of modernizing its healthcare infrastructure. With the increasing development and manufacturing of novel biologics for CNS treatment, the market is set to advance, as Chinese manufacturing firms take more outsourcing activities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Drug is Largely Adopted for CNS Treatment and Therapy?
Biologics are set to hold a share of around 68.7% in the global market, in 2023.
The blood brain barrier (BBB), which hinders attaining enough drug concentrations at sites of action, precludes many central nervous system (CNS) illnesses from being properly treated by systemically delivered medicines. Direct CNS delivery will probably play a bigger part in therapy as a result of the rising prevalence of neurodegenerative illnesses and the inability of most systemically delivered medicines to penetrate the blood-brain barrier.
This problem is solved by administering big chemicals, cells, viral vectors, oligonucleotides, and other innovative therapeutics directly to the CNS through the subarachnoid space, ventricular system, or parenchyma.
Which Drug Class of CNS Treatment and Therapy is Largely Profitable within the Global Market?
Antidepressant segment holds about one-third value share within the global market.
CNS depressants are prescribed to treat seizures, anxiety, panic attacks, and sleeplessness. They can also be administered before surgery to calm nerves and relax. Sedatives, tranquillizers, and hypnotics are medications that depress the central nervous system (CNS). These medications can reduce brain activity, making them effective for treating anxiety, panic attacks, severe stress reactions, and sleep difficulties.
Which Disease Propels the Adoption of CNS Treatment and Therapy?
Degenerative diseases are set to hold a share of around 31.7% in the global market, in 2023.
Millions of people worldwide are affected by neurodegenerative disorders. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease. According to an estimate from the Alzheimer's Disease Association, 6.2 million people in the USA had Alzheimer's disease by 2022.
Which Distribution Channel Provides the Market with a Profitable Insight for Expansion?
Hospital pharmacies segment is set to hold a share of around 48.6% in the global market, in 2023.
Increasing prevalence of neurodegenerative disorders, as well as the rising patient inflow into hospital settings are factors propelling institutional sales within the hospital pharmacies. With appropriate prescription and treatment regime, this segment is set to expand over the forecast period, owed to greater patient compliance, as well as availability of medications in-house.
Comparative View of the Adjacent CNS Treatment and Therapy Market
CNS Treatment and Therapy Market:
Attributes
CNS Treatment and Therapy Market
CAGR (2023 to 2033)
5.2%
Market Value (2023)
US$ 123.2 Billion
Growth Factor
Numerous substances are now undergoing testing. Nonselective, multipotent therapies appear to be more effective, depending on the specific experimental and clinical observations, thus propelling market growth.
Key Market Trend
The primary market players functioning in the industry have upgraded their product launches by employing new growth strategies.
Frontotemporal Dementia Management Market:
Attributes
Frontotemporal Dementia Management Market
CAGR (2023 to 2033)
6.0%
Market Value (2023)
US$ 10 Million
Growth Factor
Increased funding for drug discovery, increased research and development expenditures, and increased support from both government and non-government organizations are all driving tremendous growth.
Key Trend
The market will continue to develop as government and private organizations, including the WHO and pharmaceutical firms, place more emphasis on raising awareness of dementia and other diseases.
Antibody Therapy Market:
Attributes
Antibody Therapy Market
CAGR (2023 to 2033)
13.2%
Market Value (2023)
US$ 203.6 Billion
Growth Factor
Governmental investments in oncology technology development and research are increasing, which may provide new opportunities for the global antibody treatment market to develop.
Key Trend
The emergence of the antibody therapy business during the outbreak has been made possible by rapid product approvals for COVID-19 treatment, boosting market growth
Competitive Landscape
The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel research activities in the field of nervous system disorder diseases.
Global players with higher valuation incur higher spending on clinical trials of different products such as anesthetic anti-Parkinson drugs for launching it in market. Strategic collaborations is the major strategy adopted by such market players to expand their consumer base.
Bingen expanded its business in China after getting approval from the National Medical Products Administration (NMPA) in 2021 for its popular drug dimethyl fumarate under the brand name TECFIDERA.
To treat patients suffering from Alzheimer’s dementia the drug brexpiprazole is under development. After the successful completion of phase two trials Otsuka Pharmaceutical Co. Ltd. and Lundbeck pharmaceutical company continued its phase III clinical trials from April 2021.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the CNS treatment and therapy space, which are available in the full report.
Report Scope as per CNS Treatment and Therapy Industry Analysis
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2017 to 2022
Market Analysis
US$ Million for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa
Key Market Segments Covered
Drug, Drug Class, Disease, Distribution Channel, and Region
Key Market Segments Covered in CNS Treatment and Therapy Industry Research
Drug:
Biologics
Non Biologics
Drug Class:
Antidepressant
Analgesics
Immunomodulators
Interferons
Decarboxylase Inhibitors
Others
Disease:
Neurovascular Disease
Degenerative Disease
Infectious Disease
Mental Health
Others
Distribution Channel:
Hospital Based Pharmacies
Retail Pharmacies
Online Pharmacies
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)
Frequently Asked Questions
The market is estimated to acquire US$ 123.2 billion in 2023.
Nonselective, multipotent therapies appear to be more effective, thus propelling market growth.
The United States accounts for 31% of the market in 2023.
Germany holds a market share of nearly 6.7% in the market in 2023.
The scarcity of accessible controlled research, among the most sensitive issues is driving growth.
Table of Content
1. Market- Executive Summary | CNS Treatment and Therapy Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs
4.3. Promotional Strategies, By Key Players
4.4. Regulatory Scenario
4.5. Technology Assessment
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Market Outlook
5.1.3. Global Antibody Therapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Advancements in Drug Discovery Techniques
5.2.2. Rising Awareness on Neuropsychiatric Disorders
5.2.3. Increasing Research and Development Activities on Psychedelic Use for Mental Health
5.2.4. Rising Number of Neuroscience Drug Manufacturers
5.2.5. Rising Incidence of Psychiatric Disorders
5.2.6. Introduction of Novel Drug Delivery Systems
5.2.7. Increasing Initiatives by Government
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Drug Class
6.1.3. Revenue By Disease
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
8.3.1. Biologics
8.3.2. Non Biologics
8.4. Market Attractiveness Analysis By Drug
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
9.3.1. Antidepressant
9.3.2. Analgesics
9.3.3. Immunomodulators
9.3.4. Interferons
9.3.5. Decarboxylase Inhibitors
9.3.6. Others
9.4. Market Attractiveness Analysis By Drug Class
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Disease, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease, 2023 to 2033
10.3.1. Neurovascular Disease
10.3.2. Degenerative Disease
10.3.3. Infectious Disease
10.3.4. Mental Health
10.3.5. Others
10.4. Market Attractiveness Analysis By Disease
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa(MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. US
13.3.1.2. Canada
13.3.2. By Drug
13.3.3. By Drug Class
13.3.4. By Disease
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Drug Class
13.4.4. By Disease
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug
13.8.1.2.2. By Drug Class
13.8.1.2.3. By Disease
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug
13.8.2.2.2. By Drug Class
13.8.2.2.3. By Disease
13.8.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug
14.3.3. By Drug Class
14.3.4. By Disease
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Drug Class
14.4.4. By Disease
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Drug Class
14.8.1.2.3. By Disease
14.8.1.2.4. By Distribution Channel
14.8.2. Mexico Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Drug Class
14.8.2.2.3. By Disease
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Drug Class
14.8.3.2.3. By Disease
14.8.3.2.4. By Distribution Channel
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug
15.3.3. By Drug Class
15.3.4. By Disease
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Drug Class
15.4.4. By Disease
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Drug Class
15.8.1.2.3. By Disease
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Drug Class
15.8.2.2.3. By Disease
15.8.2.2.4. By Distribution Channel
15.8.3. France Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Drug Class
15.8.3.2.3. By Disease
15.8.3.2.4. By Distribution Channel
15.8.4. United Kingdom Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug
15.8.4.2.2. By Drug Class
15.8.4.2.3. By Disease
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug
15.8.5.2.2. By Drug Class
15.8.5.2.3. By Disease
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug
15.8.6.2.2. By Drug Class
15.8.6.2.3. By Disease
15.8.6.2.4. By Distribution Channel
15.8.7. Russia Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug
15.8.7.2.2. By Drug Class
15.8.7.2.3. By Disease
15.8.7.2.4. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Drug
16.3.3. By Drug Class
16.3.4. By Disease
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Drug Class
16.4.4. By Disease
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Drug Class
16.8.1.2.3. By Disease
16.8.1.2.4. By Distribution Channel
16.8.2. Thailand Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Drug Class
16.8.2.2.3. By Disease
16.8.2.2.4. By Distribution Channel
16.8.3. Indonesia Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Drug Class
16.8.3.2.3. By Disease
16.8.3.2.4. By Distribution Channel
16.8.4. Malaysia Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug
16.8.4.2.2. By Drug Class
16.8.4.2.3. By Disease
16.8.4.2.4. By Distribution Channel
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Drug Class
17.4.4. By Disease
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug
17.8.1.2.2. By Drug Class
17.8.1.2.3. By Disease
17.8.1.2.4. By Distribution Channel
17.8.2. Japan Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug
17.8.2.2.2. By Drug Class
17.8.2.2.3. By Disease
17.8.2.2.4. By Distribution Channel
17.8.3. South Korea Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug
17.8.3.2.2. By Drug Class
17.8.3.2.3. By Disease
17.8.3.2.4. By Distribution Channel
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug
18.3.3. By Drug Class
18.3.4. By Disease
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Drug Class
18.4.4. By Disease
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Drug Class
18.8.1.2.3. By Disease
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Drug Class
18.8.2.2.3. By Disease
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa Market Analysis 2017 to 2022and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug
19.3.3. By Drug Class
19.3.4. By Disease
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug
19.4.3. By Drug Class
19.4.4. By Disease
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug
19.8.1.2.2. By Drug Class
19.8.1.2.3. By Disease
19.8.1.2.4. By Distribution Channel
19.8.2. Türkiye Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug
19.8.2.2.2. By Drug Class
19.8.2.2.3. By Disease
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug
19.8.3.2.2. By Drug Class
19.8.3.2.3. By Disease
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug
19.8.4.2.2. By Drug Class
19.8.4.2.3. By Disease
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. Regional footprint of Players
20.4.2. Product footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. AbbVie Inc.
21.2.1.1. Overview
21.2.1.2. Key Financials
21.2.1.3. Sales Footprint
21.2.1.4. SWOT Analysis
21.2.1.5. Strategy Overview
21.2.1.5.1. Marketing Strategy
21.2.1.5.2. Product Strategy
21.2.1.5.3. Channel Strategy
21.2.2. Alkermes Plc
21.2.2.1. Overview
21.2.2.2. Key Financials
21.2.2.3. Sales Footprint
21.2.2.4. SWOT Analysis
21.2.2.5. Strategy Overview
21.2.2.5.1. Marketing Strategy
21.2.2.5.2. Product Strategy
21.2.2.5.3. Channel Strategy
21.2.3. Allergan Plc
21.2.3.1. Overview
21.2.3.2. Key Financials
21.2.3.3. Sales Footprint
21.2.3.4. SWOT Analysis
21.2.3.5. Strategy Overview
21.2.3.5.1. Marketing Strategy
21.2.3.5.2. Product Strategy
21.2.3.5.3. Channel Strategy
21.2.4. AstraZeneca Plc
21.2.4.1. Overview
21.2.4.2. Key Financials
21.2.4.3. Sales Footprint
21.2.4.4. SWOT Analysis
21.2.4.5. Strategy Overview
21.2.4.5.1. Marketing Strategy
21.2.4.5.2. Product Strategy
21.2.4.5.3. Channel Strategy
21.2.5. BIAL Group
21.2.5.1. Overview
21.2.5.2. Key Financials
21.2.5.3. Sales Footprint
21.2.5.4. SWOT Analysis
21.2.5.5. Strategy Overview
21.2.5.5.1. Marketing Strategy
21.2.5.5.2. Product Strategy
21.2.5.5.3. Channel Strategy
21.2.6. Bristol-myers Squibb
21.2.6.1. Overview
21.2.6.2. Key Financials
21.2.6.3. Sales Footprint
21.2.6.4. SWOT Analysis
21.2.6.5. Strategy Overview
21.2.6.5.1. Marketing Strategy
21.2.6.5.2. Product Strategy
21.2.6.5.3. Channel Strategy
21.2.7. Eisai Co, Ltd.
21.2.7.1. Overview
21.2.7.2. Key Financials
21.2.7.3. Sales Footprint
21.2.7.4. SWOT Analysis
21.2.7.5. Strategy Overview
21.2.7.5.1. Marketing Strategy
21.2.7.5.2. Product Strategy
21.2.7.5.3. Channel Strategy
21.2.8. Endo Pharmaceuticals
21.2.8.1. Overview
21.2.8.2. Key Financials
21.2.8.3. Sales Footprint
21.2.8.4. SWOT Analysis
21.2.8.5. Strategy Overview
21.2.8.5.1. Marketing Strategy
21.2.8.5.2. Product Strategy
21.2.8.5.3. Channel Strategy
21.2.9. Eli Lilly and Co
21.2.9.1. Overview
21.2.9.2. Key Financials
21.2.9.3. Sales Footprint
21.2.9.4. SWOT Analysis
21.2.9.5. Strategy Overview
21.2.9.5.1. Marketing Strategy
21.2.9.5.2. Product Strategy
21.2.9.5.3. Channel Strategy
21.2.10. F. Hoffmann-La Roche Ltd.
21.2.10.1. Overview
21.2.10.2. Key Financials
21.2.10.3. Sales Footprint
21.2.10.4. SWOT Analysis
21.2.10.5. Strategy Overview
21.2.10.5.1. Marketing Strategy
21.2.10.5.2. Product Strategy
21.2.10.5.3. Channel Strategy
22. Assumptions and Acronyms Used23. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 04: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 05: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
Table 06: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 07: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 08: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 09: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 10: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 11: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 12: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 13: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 14: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 15: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 16: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 17: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 18: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 19: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 20: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 21: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 22: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 23: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 24: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 25: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 26: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 27: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 28: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 29: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 30: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 31: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 32: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 33: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 34: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 35: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 36: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 37: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 38: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
Table 39: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 40: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 02: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022 to 2033
Figure 04: Global Market Value Share (%) Analysis 2023 and 2033, by Drug
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Drug
Figure 06: Global Market Attractiveness Analysis 2023 to 2033, by Drug
Figure 07: Global Market Value Share (%) Analysis 2023 and 2033, by Drug Class
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Drug Class
Figure 09: Global Market Attractiveness Analysis 2023 to 2033, by Drug Class
Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Disease
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Disease
Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Disease
Figure 13: Global Market Value Share (%) Analysis 2023 and 2033, by Distribution Channel
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Distribution Channel
Figure 15: Global Market Attractiveness Analysis 2023 to 2033, by Distribution Channel
Figure 16: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Region
Figure 18: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 19: North America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 20: North America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 21: North America Market Value Share, by Drug (2023 E)
Figure 22: North America Market Value Share, by Drug Class (2023 E)
Figure 23: North America Market Value Share, by Disease (2023 E)
Figure 24: North America Market Value Share, by Distribution Channel (2023 E)
Figure 25: North America Market Value Share, by Country (2023 E)
Figure 26: North America Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 27: North America Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 28: North America Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 31: USA Market Value Proportion Analysis, 2022
Figure 32: Global Vs. USA Growth Comparison
Figure 33: USA Market Share Analysis (%) by Drug, 2022 to 2033
Figure 34: USA Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 35: USA Market Share Analysis (%) by Disease, 2022 to 2033
Figure 36: USA Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 37: Canada Market Value Proportion Analysis, 2022
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Market Share Analysis (%) by Drug, 2022 to 2033
Figure 40: Canada Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 41: Canada Market Share Analysis (%) by Disease, 2022 to 2033
Figure 42: Canada Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 43: Latin America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 44: Latin America Market Value (US$ Million) Forecast, 2023 to 2033
Figure 45: Latin America Market Value Share, by Drug (2023 E)
Figure 46: Latin America Market Value Share, by Drug Class (2023 E)
Figure 47: Latin America Market Value Share, by Disease (2023 E)
Figure 48: Latin America Market Value Share, by Distribution Channel (2023 E)
Figure 49: Latin America Market Value Share, by Country (2023 E)
Figure 50: Latin America Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 51: Latin America Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 52: Latin America Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 53: Latin America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 54: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 55: Mexico Market Value Proportion Analysis, 2022
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Market Share Analysis (%) by Drug, 2022 to 2033
Figure 58: Mexico Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 59: Mexico Market Share Analysis (%) by Disease, 2022 to 2033
Figure 60: Mexico Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 61: Brazil Market Value Proportion Analysis, 2022
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Market Share Analysis (%) by Drug, 2022 to 2033
Figure 64: Brazil Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 65: Brazil Market Share Analysis (%) by Disease, 2022 to 2033
Figure 66: Brazil Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 67: Argentina Market Value Proportion Analysis, 2022
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Market Share Analysis (%) by Drug, 2022 to 2033
Figure 70: Argentina Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 71: Argentina Market Share Analysis (%) by Disease, 2022 to 2033
Figure 72: Argentina Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 73: Europe Market Value (US$ Million) Analysis, 2017 to 2022
Figure 74: Europe Market Value (US$ Million) Forecast, 2023 to 2033
Figure 75: Europe Market Value Share, by Drug (2023 E)
Figure 76: Europe Market Value Share, by Drug Class (2023 E)
Figure 77: Europe Market Value Share, by Disease (2023 E)
Figure 78: Europe Market Value Share, by Distribution Channel (2023 E)
Figure 79: Europe Market Value Share, by Country (2023 E)
Figure 80: Europe Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 81: Europe Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 82: Europe Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 83: Europe Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 84: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 85: UK Market Value Proportion Analysis, 2022
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Market Share Analysis (%) by Drug, 2022 to 2033
Figure 88: UK Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 89: UK Market Share Analysis (%) by Disease, 2022 to 2033
Figure 90: UK Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 91: Germany Market Value Proportion Analysis, 2022
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Market Share Analysis (%) by Drug, 2022 to 2033
Figure 94: Germany Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 95: Germany Market Share Analysis (%) by Disease, 2022 to 2033
Figure 96: Germany Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 97: Italy Market Value Proportion Analysis, 2022
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Market Share Analysis (%) by Drug, 2022 to 2033
Figure 100: Italy Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 101: Italy Market Share Analysis (%) by Disease, 2022 to 2033
Figure 102: Italy Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 103: France Market Value Proportion Analysis, 2022
Figure 104: Global Vs France Growth Comparison
Figure 105: France Market Share Analysis (%) by Drug, 2022 to 2033
Figure 106: France Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 107: France Market Share Analysis (%) by Disease, 2022 to 2033
Figure 108: France Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 109: Spain Market Value Proportion Analysis, 2022
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Market Share Analysis (%) by Drug, 2022 to 2033
Figure 112: Spain Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 113: Spain Market Share Analysis (%) by Disease, 2022 to 2033
Figure 114: Spain Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 115: Russia Market Value Proportion Analysis, 2022
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Market Share Analysis (%) by Drug, 2022 to 2033
Figure 118: Russia Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 119: Russia Market Share Analysis (%) by Disease, 2022 to 2033
Figure 120: Russia Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 121: BENELUX Market Value Proportion Analysis, 2022
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Market Share Analysis (%) by Drug, 2022 to 2033
Figure 124: BENELUX Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 125: BENELUX Market Share Analysis (%) by Disease, 2022 to 2033
Figure 126: BENELUX Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 127: East Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 128: East Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 129: East Asia Market Value Share, by Drug (2023 E)
Figure 130: East Asia Market Value Share, by Drug Class (2023 E)
Figure 131: East Asia Market Value Share, by Disease (2023 E)
Figure 132: East Asia Market Value Share, by Distribution Channel (2023 E)
Figure 133: East Asia Market Value Share, by Country (2023 E)
Figure 134: East Asia Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 135: East Asia Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 136: East Asia Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 137: East Asia Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 138: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 139: China Market Value Proportion Analysis, 2022
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Market Share Analysis (%) by Drug, 2022 to 2033
Figure 142: China Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 143: China Market Share Analysis (%) by Disease, 2022 to 2033
Figure 144: China Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 145: Japan Market Value Proportion Analysis, 2022
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Market Share Analysis (%) by Drug, 2022 to 2033
Figure 148: Japan Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 149: Japan Market Share Analysis (%) by Disease, 2022 to 2033
Figure 150: Japan Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 151: South Korea Market Value Proportion Analysis, 2022
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Market Share Analysis (%) by Drug, 2022 to 2033
Figure 154: South Korea Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 155: South Korea Market Share Analysis (%) by Disease, 2022 to 2033
Figure 156: South Korea Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 157: South Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 158: South Asia Market Value (US$ Million) Forecast, 2023 to 2033
Figure 159: South Asia Market Value Share, by Drug (2023 E)
Figure 160: South Asia Market Value Share, by Drug Class (2023 E)
Figure 161: South Asia Market Value Share, by Disease (2023 E)
Figure 162: South Asia Market Value Share, by Distribution Channel (2023 E)
Figure 163: South Asia Market Value Share, by Country (2023 E)
Figure 164: South Asia Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 165: South Asia Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 166: South Asia Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 167: South Asia Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 168: South Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 169: India Market Value Proportion Analysis, 2022
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Market Share Analysis (%) by Drug, 2022 to 2033
Figure 172: India Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 173: India Market Share Analysis (%) by Disease, 2022 to 2033
Figure 174: India Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 175: Indonesia Market Value Proportion Analysis, 2022
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Market Share Analysis (%) by Drug, 2022 to 2033
Figure 178: Indonesia Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 179: Indonesia Market Share Analysis (%) by Disease, 2022 to 2033
Figure 180: Indonesia Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 181: Malaysia Market Value Proportion Analysis, 2022
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Market Share Analysis (%) by Drug, 2022 to 2033
Figure 184: Malaysia Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 185: Malaysia Market Share Analysis (%) by Disease, 2022 to 2033
Figure 186: Malaysia Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 187: Thailand Market Value Proportion Analysis, 2022
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Market Share Analysis (%) by Drug, 2022 to 2033
Figure 190: Thailand Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 191: Thailand Market Share Analysis (%) by Disease, 2022 to 2033
Figure 192: Thailand Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 193: Oceania Market Value (US$ Million) Analysis, 2017 to 2022
Figure 194: Oceania Market Value (US$ Million) Forecast, 2023 to 2033
Figure 195: Oceania Market Value Share, by Drug (2023 E)
Figure 196: Oceania Market Value Share, by Drug Class (2023 E)
Figure 197: Oceania Market Value Share, by Disease (2023 E)
Figure 198: Oceania Market Value Share, by Distribution Channel (2023 E)
Figure 199: Oceania Market Value Share, by Country (2023 E)
Figure 200: Oceania Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 201: Oceania Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 202: Oceania Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 203: Oceania Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 204: Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 205: Australia Market Value Proportion Analysis, 2022
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Market Share Analysis (%) by Drug, 2022 to 2033
Figure 208: Australia Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 209: Australia Market Share Analysis (%) by Disease, 2022 to 2033
Figure 210: Australia Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 211: New Zealand Market Value Proportion Analysis, 2022
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Market Share Analysis (%) by Drug, 2022 to 2033
Figure 214: New Zealand Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 215: New Zealand Market Share Analysis (%) by Disease, 2022 to 2033
Figure 216: New Zealand Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 217: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022
Figure 218: Middle East & Africa Market Value (US$ Million) Forecast, 2023 to 2033
Figure 219: Middle East & Africa Market Value Share, by Drug (2023 E)
Figure 220: Middle East & Africa Market Value Share, by Drug Class (2023 E)
Figure 221: Middle East & Africa Market Value Share, by Disease (2023 E)
Figure 222: Middle East & Africa Market Value Share, by Distribution Channel (2023 E)
Figure 223: Middle East & Africa Market Value Share, by Country (2023 E)
Figure 224: Middle East & Africa Market Attractiveness Analysis by Drug, 2023 to 2033
Figure 225: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2023 to 2033
Figure 226: Middle East & Africa Market Attractiveness Analysis by Disease, 2023 to 2033
Figure 227: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 228: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033
Figure 229: GCC Countries Market Value Proportion Analysis, 2022
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Market Share Analysis (%) by Drug, 2022 to 2033
Figure 232: GCC Countries Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 233: GCC Countries Market Share Analysis (%) by Disease, 2022 to 2033
Figure 234: GCC Countries Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 235: Türkiye Market Value Proportion Analysis, 2022
Figure 236: Global Vs. Türkiye Growth Comparison
Figure 237: Türkiye Market Share Analysis (%) by Drug, 2022 to 2033
Figure 238: Türkiye Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 239: Türkiye Market Share Analysis (%) by Disease, 2022 to 2033
Figure 240: Türkiye Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 241: South Africa Market Value Proportion Analysis, 2022
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Market Share Analysis (%) by Drug, 2022 to 2033
Figure 244: South Africa Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 245: South Africa Market Share Analysis (%) by Disease, 2022 to 2033
Figure 246: South Africa Market Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 247: North Africa Market Value Proportion Analysis, 2022
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Market Share Analysis (%) by Drug, 2022 to 2033
Figure 250: North Africa Market Share Analysis (%) by Drug Class, 2022 to 2033
Figure 251: North Africa Market Share Analysis (%) by Disease, 2022 to 2033
Figure 252: North Africa Market Share Analysis (%) by Distribution Channel, 2022 to 2033
